Sky Labs Showcases 'CART BP pro' for Potential Use in Drug Clinical Trials on Global Stage

Sky Labs showcased its ring-type cuffless blood pressure monitor, “CART BP pro,” at the 9th Digital Biomarkers in Clinical Trials Summit in Basel to support drug clinical trials and Real-World Evidence (RWE). The article highlights that conventional cuff-type ABPM devices disrupt sleep for 70.2% of users and shows higher 24-hour data failure rates (50.0%) among low-tolerability patients, while CART BP pro enables measurements during daily activities and sleep without repeated arm constriction. In South Korea, CART BP pro is covered under national health insurance and officially recommended in the recently revised Korean hypertension management guidelines, and Sky Labs aims to expand clinical trial use cases via collaborations with global pharma.

Analysis

This is best read as a workflow-validation event, not a near-term revenue inflection. The economic value is in trial retention and data continuity: if cuffless monitoring reduces dropout and repeat-measurement failures, the first monetization accrues to CROs, decentralized-trial platforms, and pharma data-management budgets before it accrues to the device vendor itself. For the public names in the tape, the implication for NVS/RHHBY is marginal and mostly indirect; any benefit would show up as slightly lower trial friction, not an obvious P&L line item.

The bigger issue is adoption latency. Pharma will require side-by-side equivalence, QA/GxP integration, and likely one or two sponsor-specific pilots before this becomes standard protocol language, so the catalyst window is 1-3 quarters for headlines and 6-18 months for actual spend. The contrarian point is that consensus may overestimate how quickly “digital biomarker” credibility converts into procurement; conference attention is cheap, but switching clinical endpoints is expensive. The main falsifier is a lack of named pilot wins or any signal that regulators/statisticians reject comparability versus legacy ambulatory monitoring.

Key Decisions for Investors

• No trade in NVS or RHHBY on this release; treat it as conference optionality only. Reassess only if either name announces a named pilot, protocol amendment, or RWE partnership within the next 1-2 quarters.
• Set a watchlist on CROs and trial-enablement names such as IQV and SYNH for evidence of cuffless-vitals integration. Actionable only if multiple sponsor references emerge, implying budget conversion over the next 6-12 months.
• If forced to express the theme, use a small long XLV / short IBB pair after the first confirmed commercial pilot, not on the PR itself. Stop out if no follow-on contract wins appear by the next earnings cycle.
• Use any weakness in generic medtech/data-platform names only after confirmation of reimbursement or trial inclusion language; without that, the risk/reward is poor and the move is mostly sentiment-driven.